A scalable lentiviral vector production system based on stable producer cell lines
Sponsor
Currently, the manufacture of clinical-grade LVV is still based on transient transfection of plasmids to 293T cells which caused lots of challenges. EurekaBio has developed the EuLV system, a scalable lentiviral vector production system based on stable producer cell lines. This stable producer cell line no longer requires transient plasmid transfection; instead, all the required packaging genes (such as VSV-G, rev, gag/pol), as well as the customized therapeutic genes or commonly called gene of interest GOI, are stably inserted into the genome of the producer cell lines, and the production of lentivirus is simply achieved by chemical induction. This system is adapted to high cell density suspension culture in the chemically defined medium. EuLV increases the expressing efficiency, improves the product quality and decreases the manufacturing cost.
- Difference between manufacture LVV using stable producer cell line and transient transfection
- Key data involved in packaging and producer cell line development
- 25L scale suspension manufacture process
- EuLV system's performance based on different GOI
SPEAKERS
You might also like
Scalable solutions for optimizing lentiviral vector production
Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process
Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering
Discover the road to success for viral vector production: strategies, insights, and regulatory considerations
